107 related articles for article (PubMed ID: 20721248)
1. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
[TBL] [Abstract][Full Text] [Related]
2. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
[TBL] [Abstract][Full Text] [Related]
4. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
[TBL] [Abstract][Full Text] [Related]
5. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
[TBL] [Abstract][Full Text] [Related]
6. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
[TBL] [Abstract][Full Text] [Related]
7. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
[TBL] [Abstract][Full Text] [Related]
8. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer.
Li P; Liu K; Li L; Yang M; Gao W; Feng J; Lv Y; Qu X; Kong B
Int J Gynecol Cancer; 2011 Oct; 21(7):1248-55. PubMed ID: 21841490
[TBL] [Abstract][Full Text] [Related]
9. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.
Shao L; Cui Y; Li H; Liu Y; Zhao H; Wang Y; Zhang Y; Ng KM; Han W; Ma D; Tao Q
Clin Cancer Res; 2007 Oct; 13(19):5756-62. PubMed ID: 17908965
[TBL] [Abstract][Full Text] [Related]
10. [Pathophysiologic mechanism of CMTM5 low expression in multiple myeloma progression].
Ma Y; Shi JF; Qiu HY; Yuan J; Zhang Y; Zhou P; Xu JJ; Han QZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):58-62. PubMed ID: 30704230
[No Abstract] [Full Text] [Related]
11. [Abnormally lower expression of cmtm5 gene in bone marrow cells from patients with multiple myeloma].
Niu JH; Bao L; Zhang Y; Li JL; Li LD; Xie M; Qin YZ; Lai YY; Jiang Q; Shi HL; Liu YR; Jiang B; Chen SS; Huang XJ; Ruan GR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):363-7. PubMed ID: 20416169
[TBL] [Abstract][Full Text] [Related]
12. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.
Yuan Y; Sheng Z; Liu Z; Zhang X; Xiao Y; Xie J; Zhang Y; Xu T
J Cancer; 2020; 11(13):3762-3770. PubMed ID: 32328181
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.
Niu J; Li H; Zhang Y; Li J; Xie M; Li L; Qin X; Qin Y; Guo X; Jiang Q; Liu Y; Chen S; Huang X; Han W; Ruan G
Leuk Res; 2011 Jun; 35(6):771-6. PubMed ID: 21168207
[TBL] [Abstract][Full Text] [Related]
14. The role of polyethylenimine-functionalized gold nanoclusters carrying plasmid CMTM5 in impeding the malignant progression of prostate cancer cells by promoting EGFR endocytosis.
Li L; Li C; Miao F; Chen W; Kong X; Ye R; Feng R
Neoplasma; 2024 Feb; 71(1):48-59. PubMed ID: 38295104
[TBL] [Abstract][Full Text] [Related]
15. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha.
Guo X; Li T; Wang Y; Shao L; Zhang Y; Ma D; Han W
Biochem Biophys Res Commun; 2009 Sep; 387(1):139-42. PubMed ID: 19577543
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.
Muñoz-Moreno L; Bajo AM; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2017 May; 446():59-69. PubMed ID: 28193499
[TBL] [Abstract][Full Text] [Related]
17. In vitro modeling of HER2-targeting therapy in disseminated prostate cancer.
Andersson J; Rosestedt M; Asplund V; Yavari N; Orlova A
Int J Oncol; 2014 Nov; 45(5):2153-8. PubMed ID: 25176024
[TBL] [Abstract][Full Text] [Related]
18. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances.
Chen Z; Cui N; Zhao JS; Wu JF; Ma F; Li C; Liu XY
Eur J Histochem; 2021 Jan; 65(1):. PubMed ID: 33478201
[TBL] [Abstract][Full Text] [Related]
19. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function.
Zhang JW; Liu TF; Chen XH; Liang WY; Feng XR; Wang L; Fu SW; McCaffrey TA; Liu ML
Gene; 2017 Aug; 624():56-65. PubMed ID: 28457985
[TBL] [Abstract][Full Text] [Related]
20. CMTM5-v1 induces apoptosis in cervical carcinoma cells.
Shao L; Guo X; Plate M; Li T; Wang Y; Ma D; Han W
Biochem Biophys Res Commun; 2009 Feb; 379(4):866-71. PubMed ID: 19124004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
